These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37513666)

  • 1. Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease.
    Terasaka Y; Takahashi H; Amano K; Fujisaki K; Kita S; Kato K; Nakayama K; Yamashita Y; Nakamura S; Anzai K
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Rosso C; Guariglia M; Armandi A; Nicolosi A; Caviglia GP; Bugianesi E
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
    Lee HA; Moon H; Kim Y; Lee HA; Kim HY
    Trials; 2023 Aug; 24(1):490. PubMed ID: 37533096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.
    Amatya R; Lee D; Min KA; Shin MC
    Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.
    Rodríguez-Lara A; Rueda-Robles A; Sáez-Lara MJ; Plaza-Diaz J; Álvarez-Mercado AI
    Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
    Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
    JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crosstalking immune cells network creates a collective function beyond the function of each cellular constituent during the progression of hepatocellular carcinoma.
    Koelsch N; Mirshahi F; Aqbi HF; Saneshaw M; Idowu MO; Olex AL; Sanyal AJ; Manjili MH
    Sci Rep; 2023 Aug; 13(1):12630. PubMed ID: 37537225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of extracellular vesicles in nonalcoholic fatty liver disease.
    Jiang W; Xu Y; Chen JC; Lee YH; Hu Y; Liu CH; Chen E; Tang H; Zhang H; Wu D
    Front Endocrinol (Lausanne); 2023; 14():1196831. PubMed ID: 37534206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need.
    Kokkorakis M; Boutari C; Katsiki N; Mantzoros CS
    Metabolism; 2023 Oct; 147():155664. PubMed ID: 37517792
    [No Abstract]   [Full Text] [Related]  

  • 10. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD.
    Fernández-Sáez EM; Losarcos M; Becerril S; Valentí V; Moncada R; Martín M; Burrell MA; Catalán V; Gómez-Ambrosi J; Mugueta C; Colina I; Silva C; Escalada J; Frühbeck G; Rodríguez A
    Metabolism; 2023 Oct; 147():155663. PubMed ID: 37517791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of biochemical and genomic pathways through lycopene-loaded nano-liposomes: Alleviating insulin resistance, hepatic steatosis, and autophagy in obese rats with non-alcoholic fatty liver disease: Involvement of SMO, GLI-1, and PTCH-1 genes.
    Salem GA; Mohamed AA; Khater SI; Noreldin AE; Alosaimi M; Alansari WS; Shamlan G; Eskandrani AA; Awad MM; El-Shaer RAA; Nassan MA; Mostafa M; Khamis T
    Gene; 2023 Oct; 883():147670. PubMed ID: 37516284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Variations of
    Ding Y; Tang Z; Zhang R; Zhang M; Guan Q; Zhang L; Wang H; Chen Y; Zhang W; Wang J
    Risk Manag Healthc Policy; 2023; 16():1365-1376. PubMed ID: 37525829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High triglyceride levels increase the risk of diabetic microvascular complications: a cross-sectional study.
    Li J; Shi L; Zhao G; Sun F; Nie Z; Ge Z; Gao B; Yang Y
    Lipids Health Dis; 2023 Jul; 22(1):109. PubMed ID: 37517996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Nonalcoholic Fatty Liver Disease With Neutrophil-to-Lymphocyte Ratio and Neutrophil-Percentage-to-Albumin Ratio.
    Cucoranu DC; Pop M; Niculescu R; Kosovski IB; Toganel RO; Licu RA; Bacârea A
    Cureus; 2023 Jun; 15(6):e41197. PubMed ID: 37525801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice.
    Villani R; Magnati GP; Tuccari G; Sangineto M; Romano AD; Cassano T; Serviddio G
    Ultrasound; 2023 Aug; 31(3):177-185. PubMed ID: 37538971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicle-stimulating hormone is negatively associated with nonalcoholic fatty liver disease in a Chinese elderly population: a retrospective observational study.
    Li X; Xin N; Guo T; Wu Z; Zheng Y; Lin L; Li Q; Lin F
    BMC Endocr Disord; 2023 Aug; 23(1):165. PubMed ID: 37550673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis.
    Nunes BCM; de Moura DTH; Kum AST; de Oliveira GHP; Hirsch BS; Ribeiro IB; Gomes ILC; de Oliveira CPM; Mahmood S; Bernardo WM; de Moura EGH
    Obes Surg; 2023 Sep; 33(9):2917-2926. PubMed ID: 37537506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2.
    Huang X; Liu X; Li X; Zhang Y; Gao J; Yang Y; Jiang Y; Gao H; Sun C; Xuan L; Zhao L; Song J; Bao H; Zhou Z; Li S; Zhang X; Lu Y; Zhong X; Yang B; Pan Z
    Nat Commun; 2023 Aug; 14(1):4620. PubMed ID: 37528093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
    Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.
    Huang DQ; Singal AG; Kanwal F; Lampertico P; Buti M; Sirlin CB; Nguyen MH; Loomba R
    Nat Rev Gastroenterol Hepatol; 2023 Dec; 20(12):797-809. PubMed ID: 37537332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.